查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1801164

多發性骨髓瘤藥物市場規模、佔有率、趨勢及預測（按療法、藥物類型、最終用戶、配銷通路和地區），2025 年至 2033 年

Multiple Myeloma Drugs Market Size, Share, Trends and Forecast by Therapy, Drug Type, End User, Distribution Channel, and Region, 2025-2033
出版日期: | 出版商: IMARC | 英文 119 Pages | 商品交期: 2-3個工作天內

價格

2024年，全球多發性骨髓瘤藥物市場規模達234.6億美元。展望未來， IMARC Group預測，到2033年，該市場規模將達到368.6億美元，2025-2033年期間的複合年成長率為4.89%。目前，北美佔據市場主導地位，2024年其市佔率將超過40.7%。這種主導地位得益於先進的醫療基礎設施、創新療法的廣泛採用以及對腫瘤學研究的大量投入。主要製藥公司的佈局和優惠的報銷政策進一步提升了該地區多發性骨髓瘤藥物的市場佔有率。

精準醫療方法和生物標記驅動治療策略的興起推動了市場發展。製藥公司不斷增加對新藥研發的投資，包括雙特異性抗體和下一代蛋白酶體抑制劑，這正在拓展治療選擇。全球範圍內臨床試驗設計的改進和適應性監管途徑的建立正在加速創新藥物的上市時間。此外，診斷影像和基因組學的進步改進了疾病分類，從而實現了更個人化的治療方案。數位健康技術在監測患者反應和提高依從性方面的日益普及也發揮著重要作用。生物技術公司和研究機構之間的策略合作進一步支持了治療領域的持續進步。

在美國，多發性骨髓瘤藥物市場的成長得益於聯邦政府對腫瘤學研究的大力資助以及先進的醫療基礎設施。包括CAR-T細胞療法和抗體藥物偶聯物在內的突破性療法的高採用率正在加速市場滲透。擁有強大商業化能力的大型製藥公司的存在支持了藥物的快速部署。此外，醫療保險和私人保險公司提供的優惠報銷框架提高了患者獲得昂貴治療的管道。人口老化和預期壽命的延長也導致了疾病發生率的上升。例如，在2025年5月的ADVANCE試驗中，包含達雷妥尤單抗的四藥聯合療法（DKRd）顯示出對新診斷的多發性骨髓瘤患者的療效改善。與標準KRd方案相比，DKRd實現了更高的MRD陰性率（59% vs. 36%）和更好的近33個月無惡化存活期（86% vs. 79%），且毒性反應沒有顯著增加。這些發現支持 DKRd 作為潛在的新護理標準，使一些患者能夠推遲幹細胞移植，並強調了 MRD 陰性在指導治療決策中的重要性。

多發性骨髓瘤藥物市場趨勢：

血液系統癌症負擔加重，推動藥物需求

全球血液系統惡性腫瘤發生率的不斷上升，對多發性骨髓瘤藥物市場產生了重大影響。 2022年，這類癌症佔所有確診癌症病例的6.6%，佔相關死亡人數的7.2%，凸顯了標靶治療的迫切需求。由於多發性骨髓瘤主要源自於基因異常，其治療需要多學科方法，包括免疫調節藥物、化學治療、放射治療和幹細胞移植。血小板輸注在控制副作用方面也扮演重要角色。隨著早期檢測水準的提高，更多患者有資格接受先進的治療。全球醫療保健系統面臨著提供有效療法的壓力，這加速了骨髓瘤特異性藥物的創新，並增加了對骨髓瘤特異性藥物的投資，從而促進了多發性骨髓瘤藥物市場的樂觀前景。

科技進步加速治療創新

技術進步正在改變多發性骨髓瘤的治療，尤其是透過基於microRNA的療法和奈米藥物等創新。這些平台能夠精準靶向惡性細胞，同時最大限度地減少對健康組織的損害。一個典型的例子是Ardena位於荷蘭奧斯的奈米藥物工廠，該工廠投資2,000萬歐元，於2024年11月獲得GMP認證。該工廠支持脂質和聚合物奈米顆粒的複雜製造，這些奈米顆粒是將大分子藥物輸送到骨髓並引發抗腫瘤反應的關鍵載體。這些創新不僅可以提高治療效果，還可以透過減少併發症來降低長期醫療成本。隨著製藥公司不斷拓展其奈米技術能力，這些發展預計將在推動多發性骨髓瘤藥物市場成長方面發揮至關重要的作用。

增加生物療法的採用和醫療支出

人們對生物療法日益成長的認知正在重塑多發性骨髓瘤患者的治療偏好。這些藥物利用免疫系統來識別並清除癌細胞，提供了一種比傳統療法侵入性更小、通常更有效的替代方案。患者越來越傾向於選擇那些標靶作用機制強、全身副作用較少的療法。同時，全球醫療保健支出不斷成長（據報道，2021年全球醫療保健支出達9.8兆美元，相當於全球GDP的10.3%），使得這些先進療法的可及性更加廣泛。加之製藥業不斷成長的研究預算，生物療法在已開發市場和新興市場都越來越受歡迎。預計這一轉變將在未來幾年顯著促進多發性骨髓瘤藥物市場的擴張。

目錄

第1章：前言

第2章：範圍與方法

  • 研究目標
  • 利害關係人
  • 資料來源
    • 主要來源
    • 次要來源
  • 市場評估
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章：執行摘要

第4章：簡介

第5章：產品線評估/臨床試驗產品/臨床開發

  • PegIntron（聚乙二醇干擾素α-2b）
  • 泊馬度胺
  • 坦尼匹黴素（KOS-953）
  • MLN 9708
  • SRT-501- 012
  • BHQ880
  • 帕比司他
  • ZIO-101
  • VEGF-Trap（阿柏西普）
  • 地舒單抗
  • 哌利福星
  • 克力美德 (CC-5013)
  • 羅米地辛
  • Plitidepsin（阿普利丁）
  • 替西羅莫司（Torisel）
  • 索拉非尼
  • 貝伐單抗

第6章：全球多發性骨髓瘤藥物市場

  • 市場概覽
  • 市場表現
  • COVID-19的影響
  • 市場預測

第7章：市場區隔：依療法

  • 標靶治療
  • 生物治療
  • 化療
  • 其他

第8章：市場區隔：依藥物類型

  • 免疫調節藥物
  • 蛋白酶體抑制劑
  • 組蛋白去乙醯化酶抑制劑
  • 單株抗體藥物
  • 類固醇
  • 其他

第9章：市場區隔：依最終用戶

  • 男士
  • 女性

第10章：市場區隔：按配銷通路

  • 醫院藥房
  • 零售藥局
  • 網路藥局
  • 其他

第 11 章：市場區隔：按地區

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第 12 章：SWOT 分析

第 13 章：價值鏈分析

第 14 章：波特五力分析

第 15 章：價格指標

第 16 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Amgen Inc.
    • Bristol Myers Squibb
    • Daiichi Sankyo Co.
    • Sanofi-Aventis Groupe (Genzyme Corporation)
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Novartis International AG
    • Pfizer Inc.
    • PHARMA MAR, SA
    • Takeda Pharmaceutical Company Limited.
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112025A2169

The global multiple myeloma drugs market size was valued at USD 23.46 Billion in 2024. Looking forward, IMARC Group estimates the market to reach USD 36.86 Billion by 2033, exhibiting a CAGR of 4.89% during 2025-2033. North America currently dominates the market, holding a significant market share of over 40.7% in 2024. This dominance is driven by advanced healthcare infrastructure, high adoption of innovative therapies, and substantial investment in oncology research. The presence of key pharmaceutical companies and favorable reimbursement policies further fuel multiple myeloma drugs market share in the region.

The market is propelled by an upsurge in precision medicine approaches and biomarker-driven treatment strategies. Increasing investments by pharmaceutical companies in novel drug discovery, including bispecific antibodies and next-generation proteasome inhibitors, are expanding therapeutic options. Enhanced clinical trial designs and adaptive regulatory pathways in global regions are accelerating time-to-market for innovative drugs. Moreover, improvements in diagnostic imaging and genomics have refined disease classification, enabling more personalized treatment regimens. The growing incorporation of digital health technologies to monitor patient response and improve adherence also plays a significant role. Strategic collaborations among biotech firms and research institutions further support ongoing therapeutic advancements.

In the United States, the multiple myeloma drugs market growth is driven by robust federal funding for oncology research and the presence of an advanced healthcare infrastructure. The high adoption rate of breakthrough therapies, including CAR-T cell therapies and antibody-drug conjugates, is accelerating market penetration. The presence of major pharmaceutical players with strong commercialization capabilities supports rapid drug deployment. Additionally, favorable reimbursement frameworks through Medicare and private insurers improve access to costly treatments. An aging population and increasing life expectancy also contribute to rising disease incidence. For instance, in May 2025, a four-drug combination (DKRd) including daratumumab showed improved outcomes for newly diagnosed multiple myeloma patients in the ADVANCE trial. Compared to the standard KRd regimen, DKRd achieved higher MRD-negativity (59% vs. 36%) and better progression-free survival at nearly 33 months (86% vs. 79%), without significantly increased toxicity. These findings support DKRd as a potential new standard of care, enabling some patients to defer stem cell transplants and highlighting the importance of MRD-negativity in guiding treatment decisions.

Multiple Myeloma Drugs Market Trends:

Rising Burden of Hematological Cancers Boosting Drug Demand

The increasing incidence of hematologic malignancies globally is significantly influencing the multiple myeloma drug market. In 2022, these cancers accounted for 6.6% of all diagnosed cancer cases and 7.2% of related deaths, underscoring the critical need for targeted therapies. As multiple myeloma stems largely from genetic abnormalities, its treatment requires a multidisciplinary approach involving immunomodulatory drugs, chemotherapy, radiation, and stem cell transplants. Platelet transfusions also play a role in managing side effects. With early detection improving, more patients are eligible for advanced treatments. Healthcare systems worldwide are under pressure to offer effective therapeutics, which is accelerating innovation and boosting investments in myeloma-specific drugs, thus contributing to the positive multiple myeloma drugs market outlook.

Technological Advancements Accelerating Treatment Innovations

Technological progress is transforming multiple myeloma treatment, particularly through innovations like microRNA-based therapies and nanomedicines. These platforms enable precision targeting of malignant cells while minimizing damage to healthy tissues. A prime example is Ardena's nanomedicine facility in Oss, Netherlands, which secured GMP certification in November 2024 after a €20 million investment. This facility supports complex manufacturing of lipid and polymeric nanoparticles, delivery vehicles critical for transporting macromolecular agents to the bone marrow and triggering antitumor responses. Such innovations not only enhance treatment outcomes but also lower long-term healthcare costs by reducing complications. As pharmaceutical companies expand their nanotech capabilities, these developments are expected to play a vital role in driving the multiple myeloma drug market growth.

Increasing Biologic Therapy Adoption and Healthcare Spending

Growing awareness about biologic therapies is reshaping treatment preferences in the multiple myeloma landscape. These drugs leverage the immune system to recognize and eliminate cancer cells, offering a less invasive and often more effective alternative to conventional treatments. Patients are increasingly drawn to therapies that provide targeted mechanisms with fewer systemic side effects. Alongside this trend, rising global healthcare expenditures, reported at USD 9.8 Trillion in 2021, equating to 10.3% of global GDP, are enabling wider access to these advanced treatments. Combined with the pharmaceutical industry's expanding research budgets, biologic therapies are gaining traction across developed and emerging markets. This shift is expected to significantly contribute to the expansion of the multiple myeloma drug market in the coming years.

Multiple Myeloma Drugs Industry Segmentation:

Analysis by Therapy:

  • Targeted Therapy
  • Biologic Therapy
  • Chemotherapy
  • Others

Targeted therapy plays a pivotal role in the multiple myeloma drug market by offering a precision-based approach that directly interferes with specific molecules responsible for cancer cell growth and survival. These therapies, such as proteasome inhibitors and histone deacetylase inhibitors, provide enhanced efficacy with fewer side effects compared to traditional treatments. The increasing understanding of the genetic and molecular mechanisms of multiple myeloma has led to the development of more selective drugs. Ongoing clinical trials and regulatory approvals are further accelerating adoption. Moreover, the ability of targeted therapy to be used in combination regimens is expanding its clinical utility, driving consistent growth in this segment globally.

Biologic therapy has gained significant prominence in the multiple myeloma drug market, largely due to its ability to harness the body's immune system to combat cancer. Monoclonal antibodies, such as daratumumab and elotuzumab, have shown strong clinical success by targeting specific proteins on myeloma cells. The increasing acceptance of immunotherapy approaches and the growing demand for personalized medicine are key growth drivers for this segment. With rising awareness among healthcare providers and patients regarding the benefits of biologics, coupled with supportive reimbursement frameworks and expanding biologics pipelines, the segment is expected to experience sustained growth in both developed and emerging markets.

Chemotherapy continues to serve as a foundational component in the treatment of multiple myeloma, particularly in combination with other therapeutic classes. Although its prominence has somewhat declined with the emergence of targeted and biologic therapies, chemotherapy remains essential, especially in newly diagnosed or relapsed patients requiring rapid cytoreduction. The wide availability, proven efficacy, and cost-effectiveness of chemotherapeutic agents ensure their continued use. Advancements in formulation, including oral chemotherapies and supportive care options to manage side effects, have also contributed to maintaining its relevance. As part of combination regimens, chemotherapy enhances overall treatment outcomes, securing its ongoing role in the evolving multiple myeloma drug market.

Analysis by Drug Type:

  • Immunomodulatory Drugs
  • Proteasome Inhibitors
  • Histone Deacetylase Inhibitors
  • Monoclonal Antibody Drugs
  • Steroids
  • Others

Immunomodulatory drugs stand as the largest drug type in 2024, holding around 38.7% of the market. The immunomodulatory drugs segment dominates the multiple myeloma drug market due to its proven effectiveness in enhancing immune responses and directly targeting cancer cells. These drugs, such as lenalidomide and pomalidomide, have become foundational therapies for both newly diagnosed and relapsed patients, often used in combination with other treatments like corticosteroids and proteasome inhibitors. Their ability to modulate the tumor microenvironment, suppress abnormal plasma cells, and improve patient outcomes has led to widespread adoption. Additionally, ongoing clinical trials and regulatory approvals continue to expand their indications, reinforcing their central role in treatment protocols and sustaining their dominance in the multiple myeloma drug market.

Analysis by End User:

  • Men
  • Women

Men represent a significant segment in the multiple myeloma drug market, accounting for a higher prevalence rate compared to women. Epidemiological data indicate that men are more frequently diagnosed with multiple myeloma, which naturally drives greater demand for therapeutic interventions among this demographic. The higher incidence may be attributed to genetic, hormonal, and lifestyle factors, including greater exposure to environmental risk elements such as industrial chemicals and tobacco use. As a result, pharmaceutical companies and healthcare providers often prioritize this patient group in clinical trials and treatment planning. Increased health awareness, along with access to advanced diagnostics and treatment options, further supports the growth of this segment within the market.

Women constitute an essential and growing segment in the multiple myeloma drug market, supported by rising awareness and improving access to healthcare. Though the prevalence of multiple myeloma is relatively lower among women compared to men, the market demand from this group is expanding due to early diagnosis and increasing participation in screening programs. Advances in gender-specific research and the growing focus on tailoring therapies to address women's physiological responses contribute to better treatment outcomes. Additionally, supportive care services and educational initiatives have improved adherence to treatment regimens among female patients, fueling continued market growth in this segment.

Analysis by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Hospital pharmacies lead the market with around 57.0% of market share in 2024. The hospital pharmacies segment dominates the multiple myeloma drug market due to the complex nature of treatment regimens and the need for specialized administration and monitoring. Multiple myeloma therapies often involve intravenous drugs, combination treatments, and biologics that require hospital-grade infrastructure and professional supervision. Hospitals serve as primary points for cancer diagnosis, staging, and early treatment, making them central to drug dispensing and patient management. Furthermore, hospital pharmacies maintain a broader inventory of high-cost and high-risk oncology drugs, ensuring immediate access for patients undergoing intensive therapies. This central role in comprehensive cancer care reinforces their dominance in the multiple myeloma drug market.

Regional Analysis:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

In 2024, North America accounted for the largest market share of over 40.7%. North America dominates the multiple myeloma drug market due to its advanced healthcare infrastructure, high healthcare spending, and robust presence of leading pharmaceutical companies engaged in oncology research. The region benefits from early adoption of innovative therapies, strong regulatory support from agencies like the FDA, and widespread access to cutting-edge treatments. A high prevalence of multiple myeloma, combined with increased awareness and early diagnosis, contributes to the growing demand for targeted and biologic therapies. Additionally, favorable reimbursement policies and significant investment in clinical trials further strengthen North America's leadership in this space, ensuring its continued prominence in the multiple myeloma drug market. For instance, in June 2024, AbbVie begun its Phase III CERVINO trial for ABBV-383, a bispecific T-cell engager targeting BCMA and CD3, in patients with relapsed/refractory multiple myeloma. The global, randomized trial will enroll 380 patients who have had at least two prior therapies but not BCMA-targeted ones. Participants will receive ABBV-383 or standard available therapies. The primary endpoints are progression-free survival and overall response rate, with secondary measures including survival and disease symptom changes. ABBV-383 is dosed monthly to simplify treatment.

Key Regional Takeaways:

United States Multiple Myeloma Drugs Market Analysis

In 2024, the United States held a market share of over 86.8% in North America. The United States multiple myeloma drug market is primarily driven by the rising incidence of the disease, supported by improved diagnostic techniques that enable earlier detection and intervention. In 2025, the American Cancer Society projected approximately 36,110 new cases of multiple myeloma in the U.S. (20,030 in men, 16,080 in women) and about 12,030 related deaths (6,540 in men, 5,490 in women). In accordance with this, robust advancements in immunotherapy and precision medicine are fostering the development of novel drug classes and combination regimens, thereby impelling the market. The growing presence of a robust clinical trial pipeline, pushed by industry-academic collaborations, is further propelling market growth. Similarly, the growing awareness among healthcare providers and patients regarding early treatment options is enhancing adoption rates. Additionally, the market is benefiting from strategic mergers, acquisitions, and partnerships that strengthen research capabilities and expand portfolios. Apart from this, continued investments in biomarker-driven research and personalized medicine are driving targeted drug development and market expansion.

Europe Multiple Myeloma Drugs Market Analysis

The multiple myeloma drug market in Europe is experiencing growth due to the region's aging population, which elevates the prevalence of hematologic cancers requiring advanced treatments. It has been reported that Europe's median age is projected to rise by 5.5 years, from 44.7 in 2024 to 50.2 in 2100, with the share of people aged 80 and above expected to grow from 6.1% to 15.3%. In line with this, continued improvements in healthcare infrastructure across Europe are enhancing market accessibility. Similarly, the expansion of national cancer control programs, which promote earlier detection and the establishment of structured care pathways, is fostering market expansion. The increase in government funding dedicated to research on rare and complex diseases is driving pharmaceutical innovation. Additionally, the increasing acceptance of biosimilars is reducing treatment costs and expanding patient access to these therapies. Furthermore, the growing integration of digital health tools and electronic medical records, which improves personalized treatment planning and monitoring, is stimulating market appeal. Besides this, cross-border healthcare collaboration within the EU is strengthening knowledge exchange and accelerating the adoption of advanced multiple myeloma therapies across member states.

Asia Pacific Multiple Myeloma Drugss Market Analysis

The Asia Pacific market is largely driven by rising healthcare spending in emerging economies, which strengthens access to advanced oncology therapies. An industry report projected that India's healthcare spending will increase from 3.3% to 5% of GDP by 2030. Furthermore, rapid urbanization and changing lifestyles are increasing cancer prevalence, thereby strengthening market demand. The strong government initiatives to raise awareness of rare diseases and improve patient registries, which support early diagnosis and timely care, are bolstering market development. Additionally, strategic collaborations between regional biotech companies and global pharmaceutical firms are accelerating the transfer of technology and innovative drug development. The expansion of specialized cancer treatment centers and the growth of medical tourism infrastructure are attracting patients seeking advanced therapies. As such, India's medical tourism sector is expected to grow at a double-digit rate of 14-15% following the recent relaxation of visa rules outlined in the Union Budget 2025-26. Moreover, broader reimbursement coverage and regulatory reforms across key Asia-Pacific countries are facilitating the faster approval and availability of cutting-edge multiple myeloma treatments, thereby providing an impetus to the market.

Latin America Multiple Myeloma Drugss Market Analysis

In Latin America, the multiple myeloma drug market is growing due to the steady improvement of healthcare systems and greater public funding for oncology services across the region. Accordingly, by March 2025, Brazil's radiotherapy expansion plan, with Varian, added 92 linacs and nine HDR afterloaders, reducing wait times and enabling advanced treatments. The initiative now treats an estimated 55,000 cancer patients annually, expanding access nationwide. In addition to this, rising awareness initiatives and patient advocacy programs are encouraging earlier diagnosis and improved treatment uptake. The increasing presence of multinational pharmaceutical companies, through the formation of strategic partnerships and expansion of distribution channels, is bolstering market development. Furthermore, wider participation in international clinical trials is fostering scientific exchange and supporting faster access to advanced multiple myeloma therapies, thereby creating lucrative market opportunities.

Middle East and Africa Multiple Myeloma Drugs Market Analysis

The market in the Middle East and Africa is significantly influenced by rising healthcare expenditure and strong government initiatives to modernize oncology care. Industry analysis indicates that the UAE's healthcare spending ranks among the highest per capita globally, at approximately USD 1,200. The sector generates over USD 4.63 Billion in annual revenue and comprises 75 insurers, which provide more than 12,000 policies. Similarly, the continual development of regional cancer centers is expanding access to specialized diagnostics and advanced treatment options for multiple myeloma. Furthermore, increasing collaborations between local healthcare systems and global pharmaceutical companies are enhancing the market reach. Similarly, the growth of public-private partnerships and focused investments in training medical professionals is strengthening the oncology workforce, ensuring that patients receive high-quality, up-to-date care and improving overall treatment outcomes.

Competitive Landscape:

The competitive landscape of the multiple myeloma drug market is characterized by intense R&D activity, strategic collaborations, and continuous drug innovation. Leading players are focusing on expanding their product pipelines through the development of advanced biologics, immunotherapies, and targeted treatments. For instance, in June 2025, Glenmark's subsidiary, Ichnos Glenmark Innovation (IGI), reported promising early trial results for its cancer drug ISB 2001, targeting relapsed/refractory multiple myeloma. The novel trispecific antibody therapy showed a 79% overall response rate (ORR) among heavily pretreated patients, with 30% achieving complete or near-complete response. Six of eight patients tested negative for minimal residual disease. The trial, presented at ASCO 2025, showed manageable side effects and is moving into dose expansion to determine optimal dosing for broader testing. Regulatory approvals and fast-track designations are accelerating the launch of novel therapeutics, while mergers and licensing agreements are enhancing global reach and capabilities. Companies are increasingly investing in technologies such as CAR-T cell therapies and nanomedicine-based delivery systems to gain a competitive edge. With rising competition and robust clinical pipelines, the multiple myeloma drugs market forecast projects sustained innovation and market expansion through 2033, driven by unmet medical needs and a growing patient population worldwide.

The report provides a comprehensive analysis of the competitive landscape in the multiple myeloma drug market with detailed profiles of all major companies, including:

  • Amgen Inc.
  • Bristol Myers Squibb
  • Daiichi Sankyo Co., Ltd.
  • Sanofi-Aventis Groupe (Genzyme Corporation)
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • PHARMA MAR, S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report

  • 1.How big is the multiple myeloma drug market?
  • 2.What is the future outlook of multiple myeloma drug market?
  • 3.What are the key factors driving the multiple myeloma drug market?
  • 4.Which region accounts for the largest multiple myeloma drug market share?
  • 5.Which are the leading companies in the global multiple myeloma drug market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Pipeline Assesment/Clinical Trial Products/Clinical Developments

  • 5.1 PegIntron (Pegylated interferon alfa-2b)
  • 5.2 Pomalidomide
  • 5.3 Tanespimycin (KOS-953)
  • 5.4 MLN 9708
  • 5.5 SRT-501- 012
  • 5.6 BHQ880
  • 5.7 Panobinostat
  • 5.8 ZIO-101
  • 5.9 VEGF-Trap(Aflibercept)
  • 5.10 Denosumab
  • 5.11 Perifosine
  • 5.12 Actimid (CC-5013)
  • 5.13 Romidepsin
  • 5.14 Plitidepsin (Aplidin)
  • 5.15 Temsirolimus (Torisel)
  • 5.16 Sorafenib
  • 5.17 Bevacizumab

6 Global Multiple Myeloma Drugs Market

  • 6.1 Market Overview
  • 6.2 Market Performance
  • 6.3 Impact of COVID-19
  • 6.4 Market Forecast

7 Market Breakup by Therapy

  • 7.1 Targeted Therapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Biologic Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Chemotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Drug Type

  • 8.1 Immunomodulatory Drugs
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Proteasome Inhibitors
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Histone Deacetylase Inhibitors
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Monoclonal Antibody Drugs
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Steroids
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Others
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9 Market Breakup by End-User

  • 9.1 Men
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Women
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Distribution Channel

  • 10.1 Hospital Pharmacies
    • 10.1.1 Market Trends
    • 10.1.2 Market Forecast
  • 10.2 Retail Pharmacies
    • 10.2.1 Market Trends
    • 10.2.2 Market Forecast
  • 10.3 Online Pharmacies
    • 10.3.1 Market Trends
    • 10.3.2 Market Forecast
  • 10.4 Others
    • 10.4.1 Market Trends
    • 10.4.2 Market Forecast

11 Market Breakup by Region

  • 11.1 North America
    • 11.1.1 United States
      • 11.1.1.1 Market Trends
      • 11.1.1.2 Market Forecast
    • 11.1.2 Canada
      • 11.1.2.1 Market Trends
      • 11.1.2.2 Market Forecast
  • 11.2 Asia Pacific
    • 11.2.1 China
      • 11.2.1.1 Market Trends
      • 11.2.1.2 Market Forecast
    • 11.2.2 Japan
      • 11.2.2.1 Market Trends
      • 11.2.2.2 Market Forecast
    • 11.2.3 India
      • 11.2.3.1 Market Trends
      • 11.2.3.2 Market Forecast
    • 11.2.4 South Korea
      • 11.2.4.1 Market Trends
      • 11.2.4.2 Market Forecast
    • 11.2.5 Australia
      • 11.2.5.1 Market Trends
      • 11.2.5.2 Market Forecast
    • 11.2.6 Indonesia
      • 11.2.6.1 Market Trends
      • 11.2.6.2 Market Forecast
    • 11.2.7 Others
      • 11.2.7.1 Market Trends
      • 11.2.7.2 Market Forecast
  • 11.3 Europe
    • 11.3.1 Germany
      • 11.3.1.1 Market Trends
      • 11.3.1.2 Market Forecast
    • 11.3.2 France
      • 11.3.2.1 Market Trends
      • 11.3.2.2 Market Forecast
    • 11.3.3 United Kingdom
      • 11.3.3.1 Market Trends
      • 11.3.3.2 Market Forecast
    • 11.3.4 Italy
      • 11.3.4.1 Market Trends
      • 11.3.4.2 Market Forecast
    • 11.3.5 Spain
      • 11.3.5.1 Market Trends
      • 11.3.5.2 Market Forecast
    • 11.3.6 Russia
      • 11.3.6.1 Market Trends
      • 11.3.6.2 Market Forecast
    • 11.3.7 Others
      • 11.3.7.1 Market Trends
      • 11.3.7.2 Market Forecast
  • 11.4 Latin America
    • 11.4.1 Brazil
      • 11.4.1.1 Market Trends
      • 11.4.1.2 Market Forecast
    • 11.4.2 Mexico
      • 11.4.2.1 Market Trends
      • 11.4.2.2 Market Forecast
    • 11.4.3 Others
      • 11.4.3.1 Market Trends
      • 11.4.3.2 Market Forecast
  • 11.5 Middle East and Africa
    • 11.5.1 Market Trends
    • 11.5.2 Market Breakup by Country
    • 11.5.3 Market Forecast

12 SWOT Analysis

  • 12.1 Overview
  • 12.2 Strengths
  • 12.3 Weaknesses
  • 12.4 Opportunities
  • 12.5 Threats

13 Value Chain Analysis

14 Porters Five Forces Analysis

  • 14.1 Overview
  • 14.2 Bargaining Power of Buyers
  • 14.3 Bargaining Power of Suppliers
  • 14.4 Degree of Competition
  • 14.5 Threat of New Entrants
  • 14.6 Threat of Substitutes

15 Price Indicators

16 Competitive Landscape

  • 16.1 Market Structure
  • 16.2 Key Players
  • 16.3 Profiles of Key Players
    • 16.3.1 Amgen Inc.
      • 16.3.1.1 Company Overview
      • 16.3.1.2 Product Portfolio
      • 16.3.1.3 Financials
      • 16.3.1.4 SWOT Analysis
    • 16.3.2 Bristol Myers Squibb
      • 16.3.2.1 Company Overview
      • 16.3.2.2 Product Portfolio
      • 16.3.2.3 Financials
      • 16.3.2.4 SWOT Analysis
    • 16.3.3 Daiichi Sankyo Co.
      • 16.3.3.1 Company Overview
      • 16.3.3.2 Product Portfolio
      • 16.3.3.3 Financials
      • 16.3.3.4 SWOT Analysis
    • 16.3.4 Sanofi-Aventis Groupe (Genzyme Corporation)
      • 16.3.4.1 Company Overview
      • 16.3.4.2 Product Portfolio
      • 16.3.4.3 SWOT Analysis
    • 16.3.5 Johnson & Johnson Services, Inc.
      • 16.3.5.1 Company Overview
      • 16.3.5.2 Product Portfolio
      • 16.3.5.3 Financials
      • 16.3.5.4 SWOT Analysis
    • 16.3.6 Merck & Co., Inc.
      • 16.3.6.1 Company Overview
      • 16.3.6.2 Product Portfolio
      • 16.3.6.3 Financials
      • 16.3.6.4 SWOT Analysis
    • 16.3.7 Novartis International AG
      • 16.3.7.1 Company Overview
      • 16.3.7.2 Product Portfolio
      • 16.3.7.3 Financials
      • 16.3.7.4 SWOT Analysis
    • 16.3.8 Pfizer Inc.
      • 16.3.8.1 Company Overview
      • 16.3.8.2 Product Portfolio
      • 16.3.8.3 Financials
      • 16.3.8.4 SWOT Analysis
    • 16.3.9 PHARMA MAR, S.A.
      • 16.3.9.1 Company Overview
      • 16.3.9.2 Product Portfolio
      • 16.3.9.3 Financials
    • 16.3.10 Takeda Pharmaceutical Company Limited.
      • 16.3.10.1 Company Overview
      • 16.3.10.2 Product Portfolio
      • 16.3.10.3 Financials
      • 16.3.10.4 SWOT Analysis
    • 16.3.11 Teva Pharmaceutical Industries Ltd.
      • 16.3.11.1 Company Overview
      • 16.3.11.2 Product Portfolio
      • 16.3.11.3 Financials
      • 16.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Myeloma Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Myeloma Drugs Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Multiple Myeloma Drugs Market: Breakup by Therapy (in %), 2024
  • Figure 4: Global: Multiple Myeloma Drugs Market: Breakup by Drug Type (in %), 2024
  • Figure 5: Global: Multiple Myeloma Drugs Market: Breakup by End-User (in %), 2024
  • Figure 6: Global: Multiple Myeloma Drugs Market: Breakup by Distribution Channel (in %), 2024
  • Figure 7: Global: Multiple Myeloma Drugs Market: Breakup by Region (in %), 2024
  • Figure 8: Global: Multiple Myeloma Drugs Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 9: Global: Multiple Myeloma Drugs (Targeted Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Multiple Myeloma Drugs (Targeted Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Multiple Myeloma Drugs (Biologic Therapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Multiple Myeloma Drugs (Biologic Therapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Multiple Myeloma Drugs (Chemotherapy) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Multiple Myeloma Drugs (Chemotherapy) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Multiple Myeloma Drugs (Immunomodulatory Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Multiple Myeloma Drugs (Proteasome Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Multiple Myeloma Drugs (Histone Deacetylase Inhibitors) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Multiple Myeloma Drugs (Monoclonal Antibody Drugs) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Multiple Myeloma Drugs (Steroids) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Multiple Myeloma Drugs (Steroids) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Multiple Myeloma Drugs (Men) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Multiple Myeloma Drugs (Men) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Multiple Myeloma Drugs (Women) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Multiple Myeloma Drugs (Women) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Multiple Myeloma Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Multiple Myeloma Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: Global: Multiple Myeloma Drugs (Online Pharmacies) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: Global: Multiple Myeloma Drugs (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: Global: Multiple Myeloma Drugs (Others) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: Global: Multiple Myeloma Drugs (Others) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: North America: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: North America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: United States: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: United States: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: Canada: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: Canada: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Asia Pacific: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Asia Pacific: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: China: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: China: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: Japan: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: Japan: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: India: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: India: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: South Korea: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: South Korea: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Australia: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Australia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Indonesia: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Indonesia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Others: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: Europe: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: Europe: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: Germany: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: Germany: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: France: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: France: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: United Kingdom: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: United Kingdom: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Italy: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Italy: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Spain: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Spain: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Russia: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Russia: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Others: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Latin America: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Latin America: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Brazil: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Brazil: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Mexico: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Mexico: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 85: Others: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 86: Others: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 87: Middle East and Africa: Multiple Myeloma Drugs Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 88: Middle East and Africa: Multiple Myeloma Drugs Market: Breakup by Country (in %), 2024
  • Figure 89: Middle East and Africa: Multiple Myeloma Drugs Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 90: Global: Multiple Myeloma Drugs Industry: SWOT Analysis
  • Figure 91: Global: Multiple Myeloma Drugs Industry: Value Chain Analysis
  • Figure 92: Global: Multiple Myeloma Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Myeloma Drugs Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Therapy (in Million USD), 2025-2033
  • Table 3: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Drug Type (in Million USD), 2025-2033
  • Table 4: Global: Multiple Myeloma Drugs Market Forecast: Breakup by End-User (in Million USD), 2025-2033
  • Table 5: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Distribution Channel (in Million USD), 2025-2033
  • Table 6: Global: Multiple Myeloma Drugs Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Multiple Myeloma Drugs Market Structure
  • Table 8: Global: Multiple Myeloma Drugs Market: Key Players